Curis (CRIS) Reports Encouraging Emavusertib Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- S&P 500 ends down as oil tops $100 per barrel
- White House copper tariff plan stalls amid affordability concerns, sources say
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Crude Inventory 0.4M Barrels Last Week - EIA
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
H.C. Wainwright Reiterates Buy Rating on Curis (CRIS), Comments on Weekend Update
June 6, 2022 6:32 AM EDTH.C. Wainwright analyst Edward P. White reiterated a Buy rating and $16.00 price target on Curis (NASDAQ: CRIS)
The analyst comments "This past weekend, Curis presented updated data for emavusertib (CA-4948) in combination with Imbruvica (ibrutinib) in patients with NonHodgkins Lymphoma (NHL) at ASCO. The open-label, dose escalation, dose expansion, Phase 1/2 TakeAim Lymphoma study is evaluating emavusertib as monotherapy and in combination with Imbruvica in patients with relapsed or refractory... More
Curis (CRIS) Shares Surge 25%, Laidlaw Comments, Reiterates Buy and $22 PT
June 6, 2022 6:26 AM EDTLaidlaw analyst Yale Jen reiterated a Buy rating and $22.00 price target on Curis (NASDAQ: CRIS)
The analyst comments "The TakeAim Leukemia study data reported at the ASCO were similar to what was reported this January. In addition to the initial monotherapy results, for the TakeAim Lymphoma study, major new data were the initial emavusertib and ibrutinib combo study readouts. The key takeaways are that eight of nine evaluable patients experienced reduction in tumor burden with two CR, two PR, and five SD. Specifically, among the four who received... More
Curis (CRIS) Climbs 28% Premarket
June 6, 2022 6:15 AM EDTCuris (NASDAQ: CRIS) Climbs 28% Premarket
